Cadrenal Therapeutics Inc... (CVKD)
18.69
-0.70 (-3.61%)
At close: Jan 28, 2025, 3:08 PM
undefined% (undefined)
| Bid | 18.53 |
| Market Cap | 33.31M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -6.73 |
| PE Ratio (ttm) | -2.78 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 19.02 |
| Volume | 58,030 |
| Avg. Volume (20D) | 68,862 |
| Open | 19.50 |
| Previous Close | 19.39 |
| Day's Range | 17.77 - 19.50 |
| 52-Week Range | 5.40 - 32.55 |
| Beta | undefined |
About CVKD
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida....
Industry Biotechnology
Sector Healthcare
IPO Date Jan 20, 2023
Employees 4
Stock Exchange NASDAQ
Ticker Symbol CVKD
Website https://www.cadrenal.com
Analyst Forecast
According to 1 analyst ratings, the average rating for CVKD stock is "Strong Buy." The 12-month stock price forecast is $32, which is an increase of 71.21% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago
+17.97%
Cadrenal Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
